Citigroup Inc. reissued their buy rating on shares of Fresenius Medical Care AG (NYSE:FMS) in a research report sent to investors on Tuesday.

Several other brokerages have also recently commented on FMS. Berenberg Bank reissued a buy rating on shares of Fresenius Medical Care AG in a research report on Tuesday, August 9th. DZ Bank AG reissued a neutral rating on shares of Fresenius Medical Care AG in a research report on Thursday, August 4th. Goldman Sachs Group Inc. reissued a buy rating on shares of Fresenius Medical Care AG in a research report on Tuesday, September 13th. Jefferies Group raised shares of Fresenius Medical Care AG from an underperform rating to a hold rating in a research report on Friday, July 8th. Finally, SunTrust Banks Inc. set a $48.00 price target on shares of Fresenius Medical Care AG and gave the company a buy rating in a research report on Thursday, October 13th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $44.33.

Analyst Recommendations for Fresenius Medical Care AG (NYSE:FMS)

Fresenius Medical Care AG (NYSE:FMS) traded up 0.43% during trading on Tuesday, hitting $41.96. The company had a trading volume of 35,862 shares. The stock has a market capitalization of $25.66 billion, a price-to-earnings ratio of 23.26 and a beta of 0.58. Fresenius Medical Care AG has a 52-week low of $38.71 and a 52-week high of $47.52. The firm’s 50 day moving average is $43.52 and its 200-day moving average is $43.77.

Fresenius Medical Care AG (NYSE:FMS) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported $0.96 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.92 by $0.04. Fresenius Medical Care AG had a net margin of 6.40% and a return on equity of 9.66%. The company earned $4.42 billion during the quarter, compared to analysts’ expectations of $4.54 billion. On average, equities analysts forecast that Fresenius Medical Care AG will post $2.01 earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Rothschild Investment Corp IL acquired a new position in Fresenius Medical Care AG during the third quarter worth approximately $222,000. Genesee Valley Trust Co. raised its position in Fresenius Medical Care AG by 1.6% in the third quarter. Genesee Valley Trust Co. now owns 7,833 shares of the company’s stock worth $343,000 after buying an additional 121 shares in the last quarter. Atria Investments LLC acquired a new position in Fresenius Medical Care AG during the third quarter worth approximately $234,000. Creative Planning raised its position in Fresenius Medical Care AG by 4.7% in the third quarter. Creative Planning now owns 7,511 shares of the company’s stock worth $329,000 after buying an additional 338 shares in the last quarter. Finally, Searle & CO. acquired a new position in Fresenius Medical Care AG during the third quarter worth approximately $998,000. Institutional investors own 2.49% of the company’s stock.

Fresenius Medical Care AG Company Profile

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

5 Day Chart for NYSE:FMS

Receive News & Stock Ratings for Fresenius Medical Care AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG and related stocks with our FREE daily email newsletter.